CLINICAL RESEARCH INTEGRATES WITH GP AND PHARMACIST WORKFLOWS TO SUPPLEMENT PRACTICE REVENUE Primary health introductions to clinical trials leverages community trust in HCPs
With Charlotte Bradshaw,
CEO and Founder Evrima Technologies
SEGMENT
Filmed in Sydney | January 2025
Clinical trials are crucial to the development of evidence-based preventative medicines. In addition, participation in clinical trials can also provide patients with opportunities to access new treatments.
“Clinical trials are at the heart of medical advances which look into new ways to treat, prevent, or detect disease. Volunteers often do so to help contribute to advancing scientific research, knowing that they are participating in the hope of helping future generations,” said Charlotte Bradshaw, CEO and Founder to Evrima Technologies.
Ms Bradshaw spoke to Australian Health Journal about Evrima’s mission. As an Australian-based digital health company bringing trials to patients, GPs and pharmacists, world-class researchers are able to connect to the wider community through primary health care.
There are hundreds of clinical trials happening around the country and they can take place in hospitals, universities, private clinics and dedicated medical research institutes, yet the trusted role of a GP and pharmacists has opportunity to connect the stakeholder groups.
Research reveals that in Australia, 79% of people would consider being involved in a clinical trial, and 69% would be open to hearing about clinical trials from their GP or Health Care Practitioner. However, barriers such as time constraints, workforce shortages and lack of knowledge about the trials have been identified as barriers to GP referrals.
Each year, clinical trials are conducted to investigate treatment strategies (75%), disease prevention (15%), drugs and medicines (45%), and devices, lifestyles, and behaviours.
In Australia, trials that attract higher participation often centre around cancer and cardiovascular disease. Health conditions such as mental health, neurological and musculoskeletal trials, as well as those dealing with everyday issues including asthma and hypertension, often experience lower rates of participation.
With around 80% of clinical trials being delayed due to recruitment issues, Ms Bradshaw says that new referral platforms such as Evrima’s Evripath can simplify the process for practitioners and patients.
“We understand the daily challenges faced by GPs, but also appreciate that GPs are the gatekeepers to patient participation in clinical trials that are working towards better community outcomes,” said Ms Bradshaw.
Note: Research noted above is cited in the segment
-
Family biz succeeds in vaccine approval & distribution
It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Growing impact of blood cancer on women
According to the Leukaemia Foundation, blood cancer is one of the most urgent and under-recognised women’s health issues in Australia, with three times more Australian women diagnosed with blood cancer than ovarian and cervical cancer combined (Source: AIHW, Cancer Data in Australia, 2024).
Blood cancer has also emerged as the second most common cancer diagnosed in Australian women overall – behind only breast cancer – and the leading cancer amongst girls and women under the age of 30 (Source: AIHW, Cancer Data in Australia, 2024).
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
